Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Northwest Biotherapeutics, Inc. (NWBO) Begins Phase III Trial Of DCVax-L For Brain Cancer

|Includes: Northwest Biotherapeutics, Inc. (NWBO)

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products for the American and European markets to treat cancers more effectively than current treatments, while costing less, and without the toxicities associated chemotherapies. It is currently working on the DCVax-L personalized immune therapies for solid tumor cancers.

The company announced today that its Phase III clinical trial with DCVax-L for brain cancer has begun at King's College Hospital in the U.K., a major European center for neuro-oncology. Other sites across Europe, including three more in the U.K. and nearly 20 in Germany, are in varying stages of preparations for the trial.

This particular Phase III trial is for newly diagnosed Glioblastoma multiforme (GBM). This is the most common and lethal form of brain cancer. The trial is well under in the United States with 46 active sites presently. Total enrollment in the U.S. and Europe is expected to reach 312 patients.

Under present treatment methods, brain cancer patients have tumors recur within 7 months and they typically live less than 15 months. Northwest Biotherapeutics' DCVax-L mobilizes a patient's entire immune system to attack the full set of biomarker targets on the tumor. In prior Phase I/II trials of DCVax-L, tumors did not recur for two years and patients lived for three years. Additionally, a number of patients lived longer, with two patients exceeding 10 years.

For additional information about Northwest Biotherapeutics, its DCVax-L drug, and the Phase III trial, please visit

Please see disclaimer on the QualityStocks website: